Working… Menu

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02252172
Recruitment Status : Active, not recruiting
First Posted : September 30, 2014
Last Update Posted : March 8, 2019
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 24, 2018
Estimated Study Completion Date : March 30, 2024
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 24, 2019
October 16, 2019
2 November 7, 2019
November 25, 2019